Safety of capecitabine: A review

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 831-841

  Mikhail, Sameh E ^a   Sun, Jun F ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast cancer; Capecitabine; Colon cancer; Liver disease; Renal disease; Safety

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PHENYTOIN; SORIVUDINE; WARFARIN;

ABDOMINAL PAIN; ADVANCED CANCER; AGING; ALOPECIA; ANEMIA; ANOREXIA; APPETITE DISORDER; ASTHENIA; BILE DUCT CANCER; BREAST CANCER; BREAST METASTASIS; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLIC; COLORECTAL CANCER; COLORECTAL METASTASIS; CONJUNCTIVITIS; CONSTIPATION; CORONARY ARTERY SPASM; DEHYDRATION; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; KIDNEY CANCER; KIDNEY DISEASE; LACRIMATION; LEUKOCYTE; LEUKOPENIA; LIVER DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYOCARDIAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PARESTHESIA; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ADULT; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HUMANS; HYPERBILIRUBINEMIA; KIDNEY DISEASES; LIVER DISEASES; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PARESTHESIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VULNERABLE POPULATIONS;

EID: 77955945636     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.511610     Document Type: Review

References (72)

1. Venturini M. Rational development of capecitabine. Eur J Cancer 2002;38(Suppl 2):3-9
2. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306(6880):752-755
3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16(4):215-237
4. Regazzoni S, Pesce G, Marini G, et al. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996;7(8):807-813
5. Smith IE. Continuous infusional chemotherapy for early breast cancer: the Royal Marsden Hospital experience. Recent Results Cancer Res. 1998;152:323-327
6. Caudry M, Bonnel C, Floquet A, et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995;18(2):118-125
7. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13(6):1303-1311
8. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7(4):425-432
9. Rougier P, Paillot B, LaPlanche A, et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 1997;33(11):1789-1793
10. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16(1):301-308
11. Diasio RB. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs 1999;58(Suppl 3):119-126
12. Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park) 1998;12(10 Suppl 7):39-43
13. Bajetta E, Colleoni M, Di Bartolomeo M, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995;13(10):2613-2619
14. Ishikawa T, Utoh M, Sawada N, et al. Xeloda(capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997;16:208A
15. Ishitsuka H, Miwa M, Ishikawa T, et al. Capecitabine: an orally available fluorpyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 1995;36:407
16. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40(2):85-104
17. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008;19(5):447-464
18. Diasio RB. Sorivudine and 5-fluorouracil: a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998;46(1):1-4
19. Yan J, Tyring SK, McCrary MM, et al. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 1997;61(5):563-573
20. Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 1999;43(4):309-315
21. Ciuleanu E, Irimie A, Ciuleanu TE, et al. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. J BUON 2008;13(1):37-42
22. Lee JL, Kang YK. Capecitabine in the treatment of advanced gastric cancer. Future Oncol 2008;4(2):179-198
23. Dhillon S, Scott LJ. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs 2007;67(4):601-610
24. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13(4):566-575
25. Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002;38(Suppl 2):15-20
26. Gambill BD. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer. Clin Colorectal Cancer 2001;1(1):18-19
27. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282-2292
28. Seitz JF. 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer. Semin Oncol 2001;28(1 Suppl 1):41-44
29. Cassidy J, Dirix L, Bissett D, et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998;4(11):2755-2761
30. Lee SH, Lee J, Park J, et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004;21(3):223-231
31. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20(1):160-164
32. Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastaticbreast cancer. Ann Oncol 2001;12(9):1247-1254
33. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16(9):2977-2985
34. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-4106
35. Oshaughnessy J. Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 2002;38(Suppl 2):10-14
36. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998;16(5):1795-1802
37. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7(4):288-323
38. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18(6):1337-1345
39. Lokich J. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest 2004;22(5):713-717
40. Pentheroudakis G, Pappas P, Golfinopoulos V, et al. Weekday on-weekend off oral capecitabine: a phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy. Cancer Chemother Pharmacol 2007;60(5):733-739
41. Sakamoto J, Chin K, Kondo K, et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006;17(2):231-236
42. Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26(11):1797-1802
43. Sun JF, Wu RR, Norris C, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009;3(4):134-140
44. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41
45. Gieschke R, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn 2002;29(1):25-47
46. Szatrowski TP. Important safety-related changes to the prescribing information concerning the use of Xeloda in patients with renal impairment at baseline. 2000; Available from: MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ UCM175769.pdf. [Accessed 2 April 2010]
47. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999;5(7):1696-1702
48. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005;11(16):5886-5892
49. Furuhata T, Kawakami M, Okita K, et al. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. J Exp Clin Cancer Res 2006;25(1):79-82
50. Morel A, Boisdron-Celle M, Fey L, et al. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007;40(1-2):11-17
51. Fischer J, Schwab M, Eichelbaum M, Zanger UM. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 2003;7(2):97-105
52. Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 2000;14(1):1-16
53. Ershler WB. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Oncol Hematol 2006;58(1):68-78
54. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-2161
55. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23(13):3104-3111
56. Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13(3):484-485
57. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58(4):487-493
58. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993;50(6):441-444
59. Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003;65(2):108-112
60. Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol 2010;17(1):59-63
61. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134(1):75-82
62. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10(11):1795-1801
63. Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57(4):475-84
64. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53(13):3028-3033
65. Lemaire L, Malet-Martino MC, de Forni M, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992;66(1):119-127
66. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294(4):238-243
67. Ratain MJ. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 2002;20(6):1434-1435
68. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16(7):2297-2298
69. Xeloda (Capecitabine) package insert. 2009; Available from: www.accessdata . fda.gov/drugsatfda-docs/label/2005/ 020896s016lbl.pdf. [Accessed 3 April 2010]
70. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-1743
71. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17(2):485-493
72. Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/ metastatic colorectal cancer. Br J Cancer 2006;94(7):964-968